Empiric antibiotic therapy for moderate-to-severe community-acquired pneumonia: a systematic review and network
Maryam Ghadimi1, Reed A C Siemieniuk2, Mark Loeb3
1Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
Background:
The optimal empiric antibiotic regimen for moderate-to-severe community-acquired pneumonia (CAP) is uncertain.
Objectives:
To compare the effects of antibiotics for empiric therapy of moderate-to-severe CAP using a network meta-analysis.
Data Sources:
Medline, EMBASE, Cochrane CENTRAL, Web of Science, and CINAHL from inception to 03 July 2024.
Study Eligibility Criteria:
Randomized controlled trials (RCT).
Participants:
Adults with moderate-to-severe CAP.
Interventions:
Any empiric antibiotic regimen vs. another, placebo, or no treatment.
Assessment Of Risk Of Bias:
Paired reviewers independently assessed risk of bias using a modified Cochrane tool for assessing risk of bias in randomized trials.
Methods Of Data Synthesis:
We conducted frequentist random-effect network meta-analyses addressing patient-important outcomes and assessed the certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation approach.
Results:
In total, 143 RCTs involving 29,157 participants proved eligible. Effects are in comparison with respiratory fluoroquinolones alone. Penicillins alone (relative risks [RR]: 1.25, 95% CI: 0.93-1.67; risk difference [RD]: 33 more per 1000, 95% CI: 9 fewer to 88 more), second-generation cephalosporins alone (RR: 1.34, 95% CI: 0.89-2.02; RD: 45 more per 1000, 95% CI: 15 fewer to 135 more), and third-generation cephalosporins alone (RR: 1.32, 95% CI: 0.99-1.77; RD: 42 more per 1000, 95% CI: 1 fewer to 102 more) or combined with a macrolide (RR: 1.34, 95% CI: 0.98-1.84; RD: 45 more per 1000, 95% CI: 3 fewer to 111 more) may be inferior in reducing treatment failure (all low certainty). The evidence among other antibiotic regimens for treatment failure and among all regimens for all-cause mortality, duration of hospitalization, and adverse events suggested little to no difference (in most cases with low certainty) or was very low certainty.
Conclusions:
For empiric treatment of moderate-to-severe CAP, none of the antibiotic regimens provided convincing evidence of important differences in any of the outcomes.
Trial Registration Number:
PROSPERO (CRD42022297216).
Insights
This network meta-analysis found no convincing evidence that any antibiotic regimen is superior for treating moderate-to-severe community-acquired pneumonia (CAP). Further research is needed to determine optimal empiric antibiotic therapy for CAP.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- The optimal empiric antibiotic regimen for moderate-to-severe community-acquired pneumonia (CAP) remains uncertain.
- This uncertainty impacts clinical decision-making and patient outcomes.
Purpose of the Study:
- To compare the effectiveness of various empiric antibiotic regimens for moderate-to-severe CAP.
- To synthesize evidence from randomized controlled trials (RCTs) using a network meta-analysis.
Main Methods:
- Conducted a comprehensive literature search across multiple databases (Medline, EMBASE, Cochrane CENTRAL, Web of Science, CINAHL).
- Included RCTs involving adults with moderate-to-severe CAP, comparing different empiric antibiotic regimens.
- Assessed risk of bias and certainty of evidence using GRADE approach.
Main Results:
- 143 RCTs with 29,157 participants were analyzed.
- Penicillins, cephalosporins (alone or with macrolides) may be inferior to fluoroquinolones for treatment failure (low certainty evidence).
- Little to no difference was observed for other regimens regarding treatment failure, mortality, hospitalization, or adverse events (low to very low certainty evidence).
Conclusions:
- No antibiotic regimen demonstrated convincing evidence of superior efficacy for moderate-to-severe CAP empiric treatment.
- Current evidence suggests limited important differences among commonly used antibiotic regimens for key patient outcomes.
More Related Videos
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:30Pneumonia III: Complications and Assessment
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:28Antimicrobial Effectiveness
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care